2014-01-01から1年間の記事一覧
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial (Lancet Haematology 2014;1:e104-e1…
Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma (Br J Haematol 2015;168:55-62) プロテアソーム阻害剤であるボルテゾミブ(BOR)は，細胞の化学療法に対する感受性を増大させ…
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma (Br J Harmatol 2015;168:46-54) この単施設，オープンラベル第I/II相用量増量試験では，再発・難…
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas (JCO 2014;32:3490-…
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma (NEJM, DOI: 10.1056/NEJMoa1411321) 背景 レナリドミド＋デキサメタゾンは骨髄腫再発時において基準となる治療である．プロテアソーム阻害薬であるcarfilzomibをレナリドミド…
Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study (JCO 2014;32:3736-3743) 目的 リツキシマブ併用化学療法を受けたHBs抗原陰性，抗HBc抗…
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas (JCO 2014;32:3490-…
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis (Blood 2014;124:2498-2506) CAN2007試験は、再発した原発性ALアミロイドーシスを対象とした、bortezomib週1回または2回投与の第1/2相臨床試験…
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies (Lancet Haematology 2014;1:e17-e27) [背景] 濾胞性リンパ腫に対するfirst lineのリ…
Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study (JCO 2014;32:3137-3143) [目的] 末梢性T細胞リンパ腫(peripheral T-cell lymphoma; PTCL)の初回治療はCHOPのようなレジ…
Risk of Diabetes Mellitus in Long-Term Survivors of Hodgkin Lymphoma (JCO 2014;32:3257-3263) [目的] 近年、腹腔内に放射線治療を受けた小児癌患者で糖尿病のリスクが増加することが観察されている。ホジキンリンパ腫(HL)についても、横隔膜下に放射線…
The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas (Blood 2014;124:720-728) 頭蓋顔面領域のリンパ節外への浸潤(Ecfi)を伴うアグレッシブB細胞リンパ腫における、放射線治療と抗癌剤…
Risk of multiple primary malignancies following treatment of Hodgkin lymphoma (Blood 2014;124:319-327) 著者らは、ホジキンリンパ腫(Hodgkin lymphoma; HL)のsurvivorにおける、三次発癌のリスク、部位、時期を評価した。1965年から1995年の間にHLと診…
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomis…
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. (Blood 2014;124:63-69) この多施設参加、オープンラベル第2相試験では、新たに診断された65歳以上または自家幹細胞…
Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Pro…
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. NEJM 2014, PMID 24881631 [背景] 慢性リンパ性白血病(CLL)と小リンパ球性リンパ腫(SLL)の患者において、治療への反応期間が短かいことや、特定の染色体異常が予後の悪さと関…
The significance of combining radiotherapy with chemotherapy for early stage extranodal natural killer/T-cell lymphoma, nasal type: a systematic review and meta-analysis (Leuk Lemphoma 2014;55:1038-1048) 放射線治療は限局期の節外性NK/T細胞…
Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia JCO 2014;32:1463-1471 [目的] エン…
Complete response after autologous stem cell transplant in multiple myeloma. (Cancer Med 2014, PMID 24777883) 著者らは自家幹細胞移植(ASCT)後に完全奏功(CR)を達成した骨髄腫患者の長期予後を評価した。1990年4月から2012年6月までの間に191例がASCT…
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia (Blood 2014;123:2783-2790) Richter sydrome (RS)は予後不良と関連している。組織学的にaggressiveな慢性リンパ性白血病(histolog…
Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy.(Clin Lymphoma Myeloma Leuk 2014…
Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.(Ann Hematol 2014;93:803-810)自家幹細胞移植を併用した大量化学療法(HDT-ASCT)の後に臨床的…
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.(Biol Blood Marrow Transplant 2014;20:536-542)標準的BEAMと自家造血…
Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results.(Clin Lymphoma Myeloma Leuk 2014;14:107-113)[背景] 近年明らかになっている知見から、マントル細胞リンパ腫(MCL)では腫…
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).(Blood 2014;123:1665-1673)rituximab、bortezomib、modified hyper-CVADを組み合わせた寛解導入免疫化学…
Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study.(Blood 2014;123:2944-2952)この多国間無作為化第3相臨床試験では、未治療の低悪性…
Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index.(Genes Chromosomes Cancer 2014;53:106-116) マントル細胞リンパ腫(M…
Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study(Br J Haematol 2014;165:489-496)新たに診断されR-CHOPで治療されたびまん性大細…
この論文は、MCL-2 trialの(2008年の報告に続く)長期観察報告です。2008年の報告はこちらです。 → 参照記事Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC…
